COST-UTILITY OF BIPHASIC INSULIN ASPART COMPARED WITH PREMIXED HUMAN INSULIN IN TREATMENT OF TYPE-2 DIABETES MELLITUS IN POLAND

被引：0
|
作者：
Szmurlo, D. [1 ]
Gurda-Duda, A. [1 ]
Rys, P. [1 ]
Rutkowski, J. [1 ]
Skrzekowska-Baran, I [2 ]
Plisko, R. [1 ]
Wladysiuk, M. [1 ]
机构：
[1] HTA Consulting, Krakow, Poland
[2] Novo Nordisk Inc, Warsaw, Mazowieckie, Poland
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)75018-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A409 / A409
页数：1
相关论文
共 50 条
  • [1] Biphasic insulin aspart in the treatment of type 2 diabetes mellitus
    Cucinotta, Domenico
    Russo, Giuseppina T.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (17) : 2905 - 2911
  • [2] Biphasic insulin aspart and biphasic human insulin in type 2 diabetes: A comparison
    Jacobsen, LV
    Bell, PM
    McSorely, P
    Kristensen, A
    DIABETES, 2000, 49 : A112 - A112
  • [3] Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with type 2 diabetes
    Schmoelzer, I
    de Campo, A
    Pressl, H
    Stelzl, H
    Dittrich, P
    Oettl, K
    Wascher, TC
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (03) : 176 - 181
  • [4] Biphasic insulin aspart and biphasic human insulin compared in Type 2 diabetic subjects
    Boehm, B
    Home, P
    Kamp, N
    Lindholm, A
    DIABETOLOGIA, 2001, 44 : A210 - A210
  • [5] Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus
    Velasquez-Mieyer, Pedro A.
    Neira, Claudia P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (13) : 2377 - 2382
  • [6] COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 50 VERSUS BIPHASIC HUMAN INSULIN 50 IN PEOPLE WITH TYPE 2 DIABETES MELLITUS IN CHINA
    Wang, H.
    Liu, X.
    Wan, L.
    Sun, X.
    Chen, K.
    Zhang, Y.
    VALUE IN HEALTH, 2016, 19 (07) : A897 - A898
  • [7] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART (IDEGASP) COMPARED WITH BIPHASIC INSULIN ASPART (BIASP 30) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A MEXICAN HEALTHCARE PERSPECTIVE
    Sanchez-Pedraza, V
    Hansen, B. B.
    Gundgaard, J.
    Uranga Romano, Garca J.
    Evans, M.
    VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [8] Evaluation of the cost-utility of insulin detemir compared to insulin glargine, both in combination with insulin aspart in type-1 diabetes in Germany and Austria
    Roze, S
    Wittrup-Jensen, KU
    Valentine, WJ
    Palmer, AJ
    VALUE IN HEALTH, 2005, 8 (06) : A166 - A167
  • [9] Risk for Nocturnal Hypoglycemia With Biphasic Insulin Aspart 30 Compared With Biphasic Human Insulin 30 in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis
    Davidson, Jaime A.
    Liebl, Andreas
    Christiansen, Jens S.
    Fulcher, Greg
    Ligthelm, Robert J.
    Brown, Paul
    Gylvin, Titus
    Kawamori, Ryuzo
    CLINICAL THERAPEUTICS, 2009, 31 (08) : 1641 - 1651
  • [10] Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
    Luo, Qiong
    Zhou, Li
    Zhou, Naitong
    Hu, Ming
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
12345